Curasight technology contribute to fluorescent tumours will vastly improve survival for people with cancer
Curasight receives funding from Innovation Fund Denmark. Curasight is partner in the Fluoguide project that received the prestigieous Grand Solutions Grant from Innovation Fund Denmark to develop uPAR targeted optical imaging to be used for guiding cancer surgeons. Curasight will contribute with its longstanding and in-depth knowledge on the uPAR system as an imaging target.
Surgeons removing tumours must assess where the tumour ends and where the healthy tissue begins. This often means leaving individual cancer cells behind, enabling the cancer to return. Danish researchers can now make the cancer cells fluorescent, enabling surgeons and later robots to remove the cancer without damaging healthy tissue.